AI-generated. Cursor AI, Replit Agent, GitHub Copilot let non-devs build apps. Pricing, pitfalls, UK data protection rules — ...
The Microsoft Defender team has discovered a coordinated campaign targeting software developers through malicious repositories posing as legitimate Next.js projects and technical assessment materials, ...
Shares of Replimune Group, Inc. (REPL) have gained 0.7% over the past four weeks to close the last trading session at $7.76, but there could still be a solid upside left in the stock if short-term ...
Market researchers expect strong growth in AI infrastructure in 2026, while rising storage prices will dampen demand for end devices. Faster, bigger, smarter — the efforts of manufacturers and ...
Strip the types and hotwire the HTML—and triple check your package security while you are at it. JavaScript in 2026 is just getting started. I am loath to inform you that the first month of 2026 has ...
Hosted on MSN
Who really owns JavaScript and why it’s a problem
This video breaks down the bizarre legal battle over who owns the JavaScript name. Despite not creating or maintaining the language, Oracle controls the trademark. The story traces how this happened ...
A critical vulnerability in the popular expr-eval JavaScript library, with over 800,000 weekly downloads on NPM, can be exploited to execute code remotely through maliciously crafted input. The ...
Forbes contributors publish independent expert analyses and insights. Mark Hughes is an entertainment writer covering cinema and genre TV. This team and the rest of the crew and excellent ensemble ...
The biotech received the good news it was hoping for from a top national regulator. This concerned RP1, its advanced melanoma drug. Well before market open, Replimune announced that the U.S. Food and ...
Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...
The fate of a once-promising cancer treatment now looks uncertain at best. The meeting was conducted with U.S. Food and Drug Administration (FDA) officials, and it took place on Tuesday. The subject ...
On July 22, 2025, Replimune publicly announced that the U.S. Food and Drug Administration (FDA) had issued a "Complete Response Letter" (CRL) for its Biologics License Application (BLA) for RP1. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results